San Francisco, 22
November 2018: The global antipsychotic drugs market is
expected to reach USD 14.4 billion by 2025, according to a new report by Grand
View Research, Inc. The continuous development of better next-generation
products to overcome adverse effects and unwanted reactions of existing
products is creating demand for newer products. This factor is anticipated to
propel the market.
Rapid growth of antipsychotics can be attributed
to the rising prevalence of psychosis and other mental disorders. Governments
are focused on creating awareness regarding mental health and psychological
illnesses, which is further anticipated to drive the demand for antipsychotics.
Government bodies in collaboration with major players conduct social programs
to break the stigma related to psychotic disorders that exists in the society.
Adverse effects of antipsychotics, such as
insomnia, dry mouth, drowsiness, and blurred vision, are expected to affect the
growth by decreasing the level of acceptance in patients. In addition, the
possibility of dependency, habit formation, or addiction is affecting the
adoption of these drugs.
Established brands such as, Zyprexa lost
patent protection in October 2011, followed by Seroquel and Risperdal in 2012,
which hampers the market growth for these drugs. Also, the entry of generic
versions of these products slowed the growth of the already existing brands.
Access
Research Report of Antipsychotic Drugs
Market@ www.grandviewresearch.com/industry-analysis/antipsychotic-drugs-market
Further Key Findings From the Study Suggest:
· The growing prevalence of mental disorders,
increased investments on R&D, and rising awareness regarding these
conditions are augmenting the growth of the market.
· The first-generation of antipsychotics have
serious adverse effects and are very rarely used, hence they hold negligible
share in the market.
· The second-generation segment of drugs
accounted for the largest share in 2015 and are anticipated to further expand
during the forecast period despite the adverse effects
· As of January 2016, the third-generation
segment has only one approved product, Abilify. It has negligible adverse
effects and is expected to be the fastest growing segment over the forecast
period
· In 2015, North America dominated the global
space with the largest revenue share owing to rising prevalence of mental
illnesses
· Asia Pacific is expected to emerge as the
fastest growing region during the forecast period, mainly due to growing social
awareness regarding mental disorders and improving access to treatment
· Some of the major players in this market
are Johnson & Johnson; Pfizer, Inc.; Eli Lilly & Co.; and Bristol-Myers
Squibb
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the antipsychotic
drugs market by drug class, application, and region:
Antipsychotics Drug Class Outlook (Revenue,
USD Million; 2014 - 2025)
·
First Generation
·
Second Generation
·
Third Generation
Antipsychotics Application Outlook
(Revenue, USD Million; 2014 - 2025)
·
Schizophrenia
·
Bipolar disorder
·
Unipolar depression
·
Dementia
·
Others
Antipsychotics Regional Outlook (Revenue,
USD Million; 2014 - 2025)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
MEA
Access Press Release of
Antipsychotic Drugs Market@ www.grandviewresearch.com/press-release/global-antipsychotic-drugs-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment